- Home
- NGNE vs LXFR Comparison
NGNE vs LXFR Comparison
Compare NGNE & LXFR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NGNE
- LXFR
- Stock Information
- Founded
- NGNE 2003
- LXFR 1898
- Country
- NGNE United States
- LXFR United States
- Employees
- NGNE N/A
- LXFR N/A
- Industry
- NGNE Biotechnology: Pharmaceutical Preparations
- LXFR Major Chemicals
- Sector
- NGNE Health Care
- LXFR Industrials
- Exchange
- NGNE Nasdaq
- LXFR Nasdaq
- Market Cap
- NGNE 325.3M
- LXFR 335.4M
- IPO Year
- NGNE N/A
- LXFR 2012
- Fundamental
- Price
- NGNE $18.48
- LXFR $13.42
- Analyst Decision
- NGNE Strong Buy
- LXFR
- Analyst Count
- NGNE 7
- LXFR 0
- Target Price
- NGNE $41.86
- LXFR N/A
- AVG Volume (30 Days)
- NGNE 110.1K
- LXFR 135.6K
- Earning Date
- NGNE 08-11-2025
- LXFR 10-28-2025
- Dividend Yield
- NGNE N/A
- LXFR 3.87%
- EPS Growth
- NGNE N/A
- LXFR N/A
- EPS
- NGNE N/A
- LXFR 0.90
- Revenue
- NGNE N/A
- LXFR $403,800,000.00
- Revenue This Year
- NGNE N/A
- LXFR $3.12
- Revenue Next Year
- NGNE N/A
- LXFR $3.31
- P/E Ratio
- NGNE N/A
- LXFR $13.74
- Revenue Growth
- NGNE N/A
- LXFR 5.60
- 52 Week Low
- NGNE $6.88
- LXFR $9.41
- 52 Week High
- NGNE $74.49
- LXFR $15.64
- Technical
- Relative Strength Index (RSI)
- NGNE 35.93
- LXFR 64.00
- Support Level
- NGNE $19.59
- LXFR $12.32
- Resistance Level
- NGNE $20.46
- LXFR $13.86
- Average True Range (ATR)
- NGNE 1.23
- LXFR 0.45
- MACD
- NGNE -0.20
- LXFR 0.11
- Stochastic Oscillator
- NGNE 13.37
- LXFR 78.85
About NGNE Neurogene Inc.
Neurogene Inc is a clinical-stage biotechnology company committed to overcoming the limitations of neurological diseases into treatable conditions, by harnessing its proprietary transgene regulation technology, EXACTTM (Expression Attenuation via Construct Tuning). It is building a differentiated product portfolio of genetic medicines for rare neurological diseases with high unmet needs. The drug candidates in the company's product pipeline include NGN-401, which is in development for the treatment of Rett syndrome, using its EXACT platform, and NGN-101, a non-EXACT, conventional gene therapy development candidate for the treatment of CLN5 Batten disease, designed to deliver the CLN5 gene and packaged in an AAV9 capsid.
About LXFR Luxfer Holdings PLC
Luxfer Holdings PLC is a manufacturer industrial company innovating niche applications in materials engineering. It focuses on value creation by using its broad array of technical know-how and proprietary technologies to help create a safe, clean, and energy-efficient world. Luxfer's high-performance materials, components, and high-pressure gas containment devices are used in defense, first response and healthcare, transportation, and general industrial applications. It focuses on product lines related to magnesium alloys, zirconium chemicals, and carbon composites. Its segments are Elektron, Gas Cylinders, and Graphic Arts. It generates the majority of its revenue from Elektron and as well as Gas Cylinders.